Wilmington, Delaware, United States, March 26, 2017 -- The report “World Biopsy Devices Market - Opportunities and Forecasts 2022”, available on MarketIntelReports, estimates that the market will grow at a healthy CAGR of 5.5% till 2022.
Browse 32 Market Tables as well as 50 Figures which are spread through 158 Pages and an in-depth TOC on the “Biopsy Devices Market Forecast 2022” http://www.marketintelreports.com/report/allied0004/world-biopsy-devices-market--opportunities-and-forecasts-2014--2022
Scope & Regional Forecast of the Biopsy Devices Market
Biopsy Devices Market was valued at $1,621 million, and is expected to reach $2,399 million by 2022, supported by a CAGR of 5.5%. Biopsy is the surgical removal of tissue from an organ to determine the presence or extent of a disease, mostly cancerous and inflammatory conditions. This diagnostic procedure is generally performed by surgeons, radiologists, and interventional cardiologists, to confirm the presence of cancerous tissue. Biopsy procedures can be performed for almost any organ with the help of a specific biopsy device. Conventional biopsy devices can be complemented with advanced imaging technologies such as MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others to perform a biopsy procedure with accuracy and minimal invasiveness. These integrated procedures are important to perform biopsies in critical areas of the body such as the lungs, liver, and kidney.
Request Sample PDF Brochure @ http://www.marketintelreports.com/pdfdownload.php?id=allied0004
Increasing incidences of cancer such as breast, prostate, & lung, and rapid technological advancements have been stimulating the growth of the biopsy devices market. Moreover, increase in awareness for the diagnosis of chronic diseases such as breast cancer and lung cancer is also increasing the demand for integrated biopsy technologies such as MRI-guided biopsy. On the contrary, the use of advanced biopsy devices in developing countries is still restricted due to high cost, unawareness for the diagnosis of chronic diseases, and lack of technical expertise. However, companies are now concentrating on developing cost-effective biopsy devices, which would decrease the overall cost of biopsy procedures.
Inquiry before buying report @ http://www.marketintelreports.com/inquiry-before-buying.php?id=allied0004
Prominent Segmentations Involved in the Biopsy Devices Market
The Biopsy Devices Market can be broken down into various segmentations on the basis of -
- Type: Breast Biopsy Devices, Gastro Intestinal Biopsy Devices, Soft Tissue Biopsy Devices, Bronchial Biopsy Devices, Gynaecological Biopsy Devices, Robotic Guidance Systems and Others.
- Application: Breast Biopsy, Gastroenterology Biopsy, Prostate Biopsy, Liver biopsy, Lung biopsy, Kidney Biopsy, Gynaecological Biopsy and Others.
- Technology: MRIguided biopsy, StereotacticGuided Breast Biopsy, UltrasoundGuided Biopsy, CT guided biopsy and Others (positron emission mammography (PEM) imaging technology, Xray technology and RX technology).
- End Users: Diagnostic Centers and Hospitals.
- Geographical Location: North America, Europe, Asia-Pacific and LAMEA.
Some of the sample companies profiled in the Biopsy Devices Market report are as follows:
- Leica Biosystems (Devicor Medical products, inc.)
- Boston Scientific Corporation
- Cook Medical, Inc.
- Hologic, Inc.
- Mauna kea technologies.
- Becton Dickinson and Company (Carefusion Corp.)
- C. R. BARD, INC.
- Fujifilm Holdings Corp.
Why buy this report?
- Get a detailed picture of the Biopsy Devices Market.
- Pinpoint growth sectors and identify factors driving change.
- Understand the competitive environment, the market’s major players and leading brands.
- A five-year forecast method is used in order to assess how the market is predicted to develop.
Purchase Biopsy Devices Market Report @ http://www.marketintelreports.com/purchase.php?id=allied0004
About Us:
MarketIntelReports (MIR) aims to empower our clients to successfully manage and outperform in their business decisions. We do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
MarketIntelReports currently has more than 150,000 plus titles and 100+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Media Contact:
Company Name: Market Intel Reports
Contact Person: Mayur S
Email: [email protected]
Phone: 1-302-261-5343
Address: 2712 Centerville Road, Suite 400
City: Wilmington
State: Delaware
Country: United States


China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 



